Biomaterials Research (Sep 2022)

Nonviral delivery systems for antisense oligonucleotide therapeutics

  • Si Huang,
  • Xin-Yan Hao,
  • Yong-Jiang Li,
  • Jun‑Yong Wu,
  • Da-Xiong Xiang,
  • Shilin Luo

DOI
https://doi.org/10.1186/s40824-022-00292-4
Journal volume & issue
Vol. 26, no. 1
pp. 1 – 23

Abstract

Read online

Abstract Antisense oligonucleotides (ASOs) are an important tool for the treatment of many genetic disorders. However, similar to other gene drugs, vectors are often required to protect them from degradation and clearance, and to accomplish their transport in vivo. Compared with viral vectors, artificial nonviral nanoparticles have a variety of design, synthesis, and formulation possibilities that can be selected to accomplish protection and delivery for specific applications, and they have served critical therapeutic purposes in animal model research and clinical applications, allowing safe and efficient gene delivery processes into the target cells. We believe that as new ASO drugs develop, the exploration for corresponding nonviral vectors is inevitable. Intensive development of nonviral vectors with improved delivery strategies based on specific targets can continue to expand the value of ASO therapeutic approaches. Here, we provide an overview of current nonviral delivery strategies, including ASOs modifications, action mechanisms, and multi-carrier methods, which aim to address the irreplaceable role of nonviral vectors in the progressive development of ASOs delivery.

Keywords